Roivant Sciences Ltd. (ROIV) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $30.02: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 1.8:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality.
Roivant Sciences is a clinical-stage biopharmaceutical company advancing therapies via 'Vant' subsidiaries, including brepocitinib (TYK2/JAK1), batoclimab/IMVT-1402 (anti-FcRn), and mosliciguat. Following its October 2024 sale of Dermavant, it has no commercialized products. As... Read more
Sell if holding. Engine safety override at $30.02: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 1.8:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 52, MACD bullish. Score 5.0/10, moderate confidence.
Passes 8/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 56d clear, semi cycle peak clear, materials cycle peak clear). Suitability: moderate.
Recent developments
updated 2026-06-15Recent Developments — Roivant Sciences Ltd.
Latest news
- NEWS Guggenheim Maintains Buy on Roivant Sciences, Raises Price Target to $36 — benzinga May 26, 2026 positive
- NEWS TD Cowen Maintains Buy on Roivant Sciences, Raises Price Target to $41 — benzinga May 21, 2026 positive
- NEWS HC Wainwright & Co. Reiterates Buy on Roivant Sciences, Maintains $34 Price Target — benzinga May 21, 2026 positive
- NEWS S&P 500 Rebounds Ahead Of Nvidia's Print, Oil Sinks 5% On Iran Truce Hopes: Stock Market Today — benzinga May 20, 2026 neutral
- NEWS Crude Oil Down 5%; Lowe's Posts Upbeat Earnings — benzinga May 20, 2026 neutral
Generated 2026-06-15T18:11:47Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $30.02: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 1.8:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 52, MACD bullish. Prior stop was $28.27. Score 5.0/10, moderate confidence.
Take-profit target: $33.97 (+13.1% upside). Prior stop was $28.27. Stop-loss: $28.27.
Quality below floor (1.2 < 4.0).
Roivant Sciences Ltd. trades at a P/E of N/A (forward -19.3). TrendMatrix value score: 6.0/10. Verdict: Sell.
19 analysts cover ROIV with a consensus score of 4.3/5. Average price target: $39.
What does Roivant Sciences Ltd. do?Roivant Sciences is a clinical-stage biopharmaceutical company advancing therapies via 'Vant' subsidiaries, including...
Roivant Sciences is a clinical-stage biopharmaceutical company advancing therapies via 'Vant' subsidiaries, including brepocitinib (TYK2/JAK1), batoclimab/IMVT-1402 (anti-FcRn), and mosliciguat. Following its October 2024 sale of Dermavant, it has no commercialized products. As of March 31, 2025, it held $4.9B in cash to fund ongoing clinical programs.